title: Microbial carriage, sepsis, infection and acute GVHD in the first 25 BMT at the Royal Liverpool Children's Hospital.
abstract: The first 25 BMTs at the Royal Liverpool Children's Hospital (Alder Hey) were performed between April 1987 and July 1991. The aim of this report is to evaluate selective decontamination of the digestive tract (SDD) during the first post-BMT month in this series of 14 allografts and 11 autografts. SDD is a method used to abolish carriage of potentially pathogenic microorganisms including yeasts, Staphylococcus aureus and Gram-negative bacilli (GNB). Chlorhexidine mouth wash was used to decontaminate the oropharynx, and neomycin, colistin (polymyxin E) and nystatin (NEOCON) were given to eradicate gut carriage. Oropharyngeal decontamination was successful in 48% of patients, gut carriage was abolished in 60%, and eradication of the carrier state at both sites was achieved in 33%. A septic response was seen in 76% of children and 36% developed septicaemia (indigenous Gram-positive cocci only). A low carriage index for the target microorganisms during the study manoeuvre of SDD was associated with negative blood cultures (p < 0.01). Acute GVHD occurred in 28% of allografts, but was seen in none of the successfully decontaminated children (p < 0.05). It is concluded that septicaemia from yeasts and GNB, but not the septic response, were successfully prevented by SDD.
authors: Department of Haematology/Oncology, Royal Liverpool Children's Hospital, UK.
authors: L E
authors: LE
authors: Rhodes
authors: H K
authors: HK
authors: van Saene
authors: S
authors: S
authors: White
authors: S
authors: S
authors: Fairclough
authors: L M
authors: LM
authors: Ball
authors: J
authors: J
authors: Martin
mesh_terms: D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000401:mortality; D002353:Carrier State / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D002710:Chlorhexidine / Q000008:administration & dosage; D003091:Colistin / Q000008:administration & dosage; D004064:Digestive System / Q000382:microbiology*; D004198:Disease Susceptibility; D004359:Drug Therapy, Combination / Q000008:administration & dosage; D004739:England / Q000453:epidemiology; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D009355:Neomycin / Q000008:administration & dosage; D009503:Neutropenia / Q000150:complications; D009761:Nystatin / Q000008:administration & dosage; D011292:Premedication; D012189:Retrospective Studies; D018805:Sepsis / Q000453:epidemiology / Q000517:prevention & control; D016019:Survival Analysis
chemical_list: D009761:Nystatin; D009355:Neomycin; D002710:Chlorhexidine; D003091:Colistin